Antibody

189개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved189 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleTianjin Medical University Canc…Preclinical

Enituzumab injection+Abesili tablets+Anastrozole tablets (Enituzumab injection+Abesili tablets+Anastrozole tablets)

Advanced HR+ HER2 Negative Breast Carcinoma · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#AdvancedHR+HER2NegativeBreastCar+1
Trials 1Status Active
AntibodyLimited DatastaleFox Chase Cancer CenterPhase 2

pembrolizumab (Keytruda, Epacadostat + pembrolizumab)

Recurrent/ Metastatic Endometrial Carcinoma · Recurrent/ Metastatic Endometrial Carcin

#RecurrentMetastaticEndometrialCa#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Discontinued
AntibodyLimited DatastaleBoehringer IngelheimPhase 1

Ezabenlimab (Ezabenlimab)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#monoclonal-antibody#Boehringer
Trials 1Status Recruiting
AntibodyLimited DatastaleMedical University of ViennaPhase 2

atezolizumab (Tecentriq, FMT combined with Atezolizumab plus Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Medical
Trials 1Status Active
AntibodyLimited DatastaleSuzhou Kintor Pharmaceutical In…Phase 2

nivolumab (Opdivo, GT90001 and Nivolumab)

Metastatic Hepatocellular Carcinoma; HCC · Metastatic Hepatocellular Carcinoma

#MetastaticHepatocellularCarcinom#Antibody#Phase2#monoclonal-antibody#HCC+1
Trials 1Status Active
AntibodyLimited DatastaleHookipa Biotech GmbHPhase 2

pembrolizumab (Keytruda, HB-202 / HB-201 alternating intravenous administration + pembrolizumab.)

HPV-Related Squamous Cell Carcinoma · HPV-Related Squamous Cell Carcinoma

#HPV-RelatedSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Hookipa
Trials 1Status Active
AntibodyLimited DatastaleIkena OncologyPhase 1

nivolumab (Opdivo, IK-175 + nivolumab)

Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#monoclonal-antibody#HeadandNeckCancer+1
Trials 1Status Discontinued
AntibodyLimited DatastaleIkena OncologyPhase 1

nivolumab (Opdivo, IK-175 and nivolumab)

Urothelial Carcinoma; Urothelial Carcinoma Bladder · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase1#monoclonal-antibody#UrothelialCarcinomaBladder+1
Trials 1Status Active
AntibodyLimited DatastaleGregory DanielsPhase 2

nivolumab (Opdivo, IL-2 and Nivolumab)

Melanoma Stage Iv; Renal Cell Carcinoma, Metastatic · Melanoma Stage Iv

#MelanomaStageIv#Antibody#Phase2#monoclonal-antibody#RenalCellCarcinoma+2
Trials 1Status Discontinued
AntibodyLimited DatastaleImmuneering CorporationPhase 2

Treatment Group E (IMM-1-104 + pembrolizumab, IMM-1-104 + pembrolizumab (Treatment Group E))

Advanced Solid Tumor; Pancreatic Adenocarcinoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#monoclonal-antibody#PancreaticAdenocarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAssociazione Volontari Pazienti…Phase 3

INDUCTION CTx (TPF, INDUCTION CTx, INDUCTION CTx(TPF)+(RT+CETUXIMAB))

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Associazione
Trials 1Status Active
AntibodyLimited DatastaleMerckPreclinical

pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab (Immune Checkpoint Inhibitors, Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab))

Esophageal Squamous Cell Carcinoma (ESCC) · Esophageal Squamous Cell Carcinoma (ESCC

#EsophagealSquamousCellCarcinomaE#Antibody#Preclinical#monoclonal-antibody#Merck
Trials 1Status Recruiting
AntibodyLimited DatastaleSir Run Run Shaw HospitalPhase 2

Ipalolimab and Tovorilimab (Ipalolimab and Tovorilimab)

dMMR/MSI-H-type Rectal Adenocarcinoma · dMMR/MSI-H-type Rectal Adenocarcinoma

#dMMRMSI-H-typeRectalAdenocarcino#Antibody#Phase2#monoclonal-antibody#dMMR+2
Trials 1Status Recruiting
AntibodyLimited DatastaleTianjin Medical University Canc…Phase 2

Iparomlimab and tuvonralimab (Iparomlimab and tuvonralimab)

HCC - Hepatocellular Carcinoma; Iparomlimab and Tuvonralimab Injection · mCRC

#mCRC#Antibody#Phase2#monoclonal-antibody#HCC-HepatocellularCarcinoma+2
Trials 1Status Recruiting
AntibodyLimited DatastaleGroupe Oncologie Radiotherapie …Phase 3

Ligufalimab (Ligufalimab)

Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) · Squamous Cell Carcinoma Head and Neck Ca

#SquamousCellCarcinomaHeadandNeck#Antibody#Phase3#monoclonal-antibody#Groupe
Trials 1Status Recruiting
AntibodyLimited DatastaleAbbViePhase 3

Livmoniplimab (Livmoniplimab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#AbbVie
Trials 1Status Recruiting
AntibodyLimited DatastaleMedivirPhase 2

pembrolizumab (Keytruda, MIV-818, MIV-818 (fostroxacitabine bralpamide) + pembrolizumab, fostroxacitabine bralpamide)

Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#IntrahepaticCholangiocarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleCentre Hospitalier Universitair…Phase 2

durvalumab (Imfinzi, MP0317 + Gemcitabine + Cisplatine + Durvalumab)

Advanced Biliary Tract Carcinoma · Advanced Biliary Tract Carcinoma

#AdvancedBiliaryTractCarcinoma#Antibody#Phase2#monoclonal-antibody#Centre
Trials 1Status Recruiting
AntibodyLimited DatastaleLei LiuPhase 2

MRG003 combined with Pucotenlimab (MRG003 combined with Pucotenlimab)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Lei
Trials 1Status Recruiting
AntibodyLimited DatastaleLei LiuPhase 2

MRG003 combined with Pucotenlimab+Cisplatin (MRG003 combined with Pucotenlimab+Cisplatin)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Lei
Trials 1Status Recruiting

6 / 10 pages

← PreviousNext →